Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficiency of MSCs in Treating COVID-19 Pneumonia
NCT04252118Phase 1Unknown
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Jan 2020
- Primary completion
- Dec 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of mesenchymal stem cells in COVID-19 pneumonia (2 arms), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoints: Size of lesion area by chest radiograph or CT at Day 28 and Side effects in the MSCs treatment group at Day 180. Status: unknown.
02
Drugs
mesenchymal stem cells
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04252118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04252118.